Phathom Pharmaceuticals Inc’s recently made public that its Principal Accounting Officer Breedlove Robert Charles unloaded Company’s shares for reported $5573.0 on Sep 05 ’25. In the deal valued at $12.09 per share,461 shares were sold. As a result of this transaction, Breedlove Robert Charles now holds 47,931 shares worth roughly $0.55 million.
Then, Breedlove Robert Charles sold 1,692 shares, generating $14,152 in total proceeds. Upon selling the shares at $8.36, the Principal Accounting Officer now owns 48,392 shares.
Before that, Topper James N bought 3,780 shares. Phathom Pharmaceuticals Inc shares valued at $14,609 were divested by the Director at a price of $3.86 per share. As a result of the transaction, Topper James N now holds 59,403 shares, worth roughly $0.68 million.
Cantor Fitzgerald initiated its Phathom Pharmaceuticals Inc [PHAT] rating to an Overweight in a research note published on February 14, 2025; the price target was $23. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early May with a ‘”a Buy”‘ rating. Needham also remained covering PHAT and reiterated its “Buy” recommendation on January 05, 2024. H.C. Wainwright started covering the stock on August 09, 2023. It rated PHAT as “a Buy”.
Price Performance Review of PHAT
On Monday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock fall -3.04% to $11.48. Over the last five days, the stock has lost -7.64%. Phathom Pharmaceuticals Inc shares have fallen nearly -38.61% since the year began. Nevertheless, the stocks have risen 41.38% over the past one year.
How much short interest is there in Phathom Pharmaceuticals Inc?
A steep rise in short interest was recorded in Phathom Pharmaceuticals Inc stocks on 2025-08-29, growing by 3.08 million shares to a total of 13.17 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 10.09 million shares. There was a rise of 23.38%, which implies that there is a positive sentiment for the stock.
